

Welcome to STN International! Enter x:x

LOGINID:sssptal600rxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Feb 24	PCTGEN now available on STN
NEWS	4	Feb 24	TEMA now available on STN
NEWS	5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26	PCTFULL now contains images
NEWS	7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24	PATDPAFULL now available on STN
NEWS	9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11	Display formats in DGENE enhanced
NEWS	11	Apr 14	MEDLINE Reload
NEWS	12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	13	AUG 15	Indexing from 1937 to 1946 added to records in CA/CAPLUS
NEWS	14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28	RDISCLOSURE now available on STN
NEWS	16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	19	May 19	Simultaneous left and right truncation added to WSCA
NEWS	20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06	PASCAL enhanced with additional data
NEWS	23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25	HSDB has been reloaded
NEWS	25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21	Identification of STN records implemented
NEWS	27	Jul 21	Polymer class term count added to REGISTRY
NEWS	28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS	29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	30	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	31	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS	32	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS	33	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS	34	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS	35	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	36	AUG 18	Simultaneous left and right truncation added to PASCAL

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT

MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:32:03 ON 18 AUG 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.10	2.10

FILE 'REGISTRY' ENTERED AT 12:38:11 ON 18 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 AUG 2003 HIGHEST RN 567484-39-3

DICTIONARY FILE UPDATES: 15 AUG 2003 HIGHEST RN 567484-39-3

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10050376.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:38:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 16548 TO ITERATE

6.0% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 323266 TO 338654
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 12:38:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 328733 TO ITERATE

100.0% PROCESSED 328733 ITERATIONS 177 ANSWERS
SEARCH TIME: 00.00.26

L3 177 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	150.25

FILE 'CAPLUS' ENTERED AT 12:39:02 ON 18 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Aug 2003 VOL 139 ISS 8
FILE LAST UPDATED: 17 Aug 2003 (20030817/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3


L4 23 L3

=> d ibib abs hitstr 1-23

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:376819 CAPLUS
DOCUMENT NUMBER: 138:385173
TITLE: Preparation of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating Alzheimer's disease
INVENTOR(S): Varghese, John; Maillard, Michel; Jagodzinska, Barbara; Beck, James P.; Gailunas, Andrea; Fang, Larry; Sealy, Jennifer; Tenbrink, Ruth; Freskos, John; Mickelson, John; Samala, Lakshman; Hom, Roy
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
SOURCE: PCT Int. Appl., 1243 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040096	A2	20030515	WO 2002-US36072	20021108
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003040096	A2	20030515	WO 2002-XA36072	20021108
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2001-337122P	P 20011108
			US 2001-344086P	P 20011228
			US 2002-345635P	P 20020103
			WO 2002-US36072	A 20021108
OTHER SOURCE(S):	MARPAT 138:385173			
GI				

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
Absolute stereochemistry.



RN 388066-92-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-[[[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]amino]carbonyl]-5-methylbenzoyl]-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 388067-16-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-[[[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]amino]carbonyl]-5-methylbenzoyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, alkyl, haloalkyl, alkenyl, etc.; R3 = H, alkyl, haloalkyl, alkenyl, etc.; or R2 and R3 are taken together with the carbon to which they are attached to form a carbocycle of 3-7 carbon atoms, optionally where one carbon atom is replaced by a heteroatom selected from the group consisting of O, S, SO2, (un)substituted NH; R4 = alkyl, haloalkyl, hydroxyalkyl, etc.; R5 = R6X (wherein X = CO, SO2, (un)substituted CH2; R6 = (un)substituted Ph, naphthyl, indanyl, etc.); R25 = H, alkyl, alkoxy, etc.] which have activity as inhibitors of .beta.-secretase and are therefore useful in treating a variety of disorders such as Alzheimer's disease, were prepd. E.g., a multi-step synthesis of (1S,2R)-II, starting from (2S)-2-[(tert-butoxycarbonyl)amino]-3-(3,5-difluorophenyl)propanoic acid, was given. The compds. I showed IC50 of < 20 .mu.M in cell free inhibition assay utilizing a synthetic APP substrate. This is a Part 1 of 1-2 series.

IT 388066-79-3P 388066-92-0P 388067-16-1P
527714-28-9P 527714-81-4P 527714-85-8P
527716-76-3P 527717-66-4P 527726-64-3P
527727-13-5P 527727-30-6P 527728-42-3P
527728-43-4P 527728-70-7P 527728-83-2P
527728-97-8P 527728-98-9P 527729-08-4P
527729-09-5P 527729-12-0P 527730-27-4P
527732-52-1P 528116-70-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating Alzheimer's disease)

RN 388066-79-3 CAPLUS


CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(3-iodophenyl)methyl]amino]propyl]-4-hydroxy-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 527714-28-9 CAPLUS

CN Acetic acid, 2-ethyl-1-[2-hydroxy-3-[[[3-hydroxy-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-4-phenylbutyl]hydrazide (9CI) (CA INDEX NAME)




RN 527714-81-4 CAPLUS

CN Benzoic acid, 3-ethyl-, 2-ethyl-2-[2-hydroxy-3-[[[3-hydroxy-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-4-phenylbutyl]hydrazide (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




RN 527714-85-8 CAPLUS
CN Pentanoic acid, 4-methyl-, 2-ethyl-2-[2-hydroxy-3-[[3-hydroxy-4-(1-pyrrolidinyl)carbonyl]benzoyl]amino]-4-phenylbutyl]hydrazide (9CI) (CA INDEX NAME)

PAGE 2-A




L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 527716-76-3 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-[[2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 527717-66-4 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-[[2S)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 527726-64-3 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-methyl-5-[(2-propyl-1-pyrrolidinyl)carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 527727-13-5 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-[[2R,5R)-2,5-dimethyl-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 527727-30-6 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-[[2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-(2-oxazolyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 527728-42-3 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-(1-methylethyl)phenyl)methyl]amino]propyl]-3-[[2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 527728-43-4 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethynylphenyl)methyl]amino]-2-hydroxypropyl]-3-[[2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 527728-70-7 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethynylphenyl)methyl]amino]-2-hydroxypropyl]-3-[(ethylmethylamino)sulfonyl]-5-[[2S)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 527728-98-9 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[1-(3-ethynylphenyl)cyclopropyl]amino]-2-hydroxypropyl]-3-[[2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 527728-97-8
CMF C36 H39 F2 N3 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 527729-08-4 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethynylphenyl)methyl]amino]-2-hydroxypropyl]-3-[[1,1-dimethylethyl]amino]sulfonyl]-5-[[2S)-2-(methoxymethyl)-1-

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 527728-83-2 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethynylphenyl)methyl]amino]-2-hydroxypropyl]-3-[[2S)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-[[2R)-2-(methoxymethyl)-1-pyrrolidinyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 527728-97-8 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[1-(3-ethynylphenyl)cyclopropyl]amino]-2-hydroxypropyl]-3-[[2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

Absolute stereochemistry.



RN 527729-09-5 CAPLUS
CN Benzamide, 3-[[2S)-2-butyl-1-pyrrolidinyl]carbonyl]-N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethynylphenyl)methyl]amino]-2-hydroxypropyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 527729-12-0 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethynylphenyl)methyl]amino]-2-hydroxypropyl]-3-methyl-5-[[2R)-2-(propoxymethyl)-1-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 527730-27-4 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-methyl-5-[[2S)-2-propyl-1-pyrrolidinyl]carbonyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1
CRN 527730-26-3
CMF C35 H43 F2 N3 O3

Absolute stereochemistry.




CM 2
CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 527732-52-1 CAPLUS


L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-3-[[2S)-2-ethyl-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528116-70-3 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[1-(3-ethylphenyl)cyclopropyl]amino]-2-hydroxypropyl]-3-[[2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:794312 CAPLUS
DOCUMENT NUMBER: 137:310704
TITLE: Preparation of N-[(pyrrolidinocarbonyl)phenyl]amidinop henylacetamides and analogs as antithrombotics
INVENTOR(S): Ries, Uwe Joerg; Priepke, Henning; Nar, Herbert; Stassen, Jean-marie; Wienen, Wolfgang
PATENT ASSIGNEE(S): Germany
SOURCE: U.S. Pat. Appl. Publ., 31 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002151534	A1	20021017	US 2002-50376	20020116
DE 10104597	A1	20020808	DE 2001-10104597	20010202
DE 10136435	A1	20030213	DE 2001-10136435	20010726
PRIORITY APPLN. INFO.:			DE 2001-10104597 A	20010202
			US 2001-268569P P	20010215
			DE 2001-10136435 A	20010726

OTHER SOURCE(S): MARPAT 137:310704
GI



AB The title compds., [e.g. (I)], wherein m = 0, 1, 2; n = 0, 1; A = (C1-C3)alkylene, a bond, etc.; R1 = amino, (C1-C5)alkylamino, (C3-C7)cycloalkylamino, phenyl(C1-C3)alkylamino, etc.; R2 = H, F, Cl, Br, etc.; R3 = H, (C1-C3)alkyl; R4 = H, (C1-C3)alkyl; Ar = substituted Ph, naphthyl] were prepd. Thus, N-(5-carbamimidoyl-2-hydroxybenzyl)-3-chloro-4-(pyrrolidin-1-ylcarbonyl)benzamide hydrochloride was prepd. by a multistep synthesis. The prepd. compds. are useful as antithrombotic agents. Data for biol. activity of title compds. were given.
IT 445256-53-1P 446025-38-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of N-[(pyrrolidinocarbonyl)phenyl]amidinophenylacetamides and analogs as antithrombotics)

RN 445256-53-1 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monoacetate (9CI) (CA INDEX NAME)

CM 1
CRN 445256-32-6

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CMF C24 H28 N4 O4


PAGE 1-A



PAGE 2-A




CM 2
CRN 64-19-7
CMF C2 H4 O2




RN 446025-38-3 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● HCl

IT 445256-14-4P 445256-20-2P 445256-36-0P
 445256-38-2P 445256-41-7P 445256-42-8P
 445256-47-3P 446025-30-5P 446025-31-6P
 446025-37-2P 446025-39-4P 446025-41-8P
 446025-43-0P 446025-44-1P 446025-45-2P
 446025-46-3P 446025-47-4P 446025-48-5P
 446025-50-9P 446025-51-0P 446025-52-1P
 446025-53-2P 446025-54-3P 446025-55-4P
 446025-56-5P 446025-57-6P 446025-58-7P
 446025-59-8P 446025-60-1P 446025-61-2P
 446025-62-3P 446025-63-4P 446025-64-5P
 446025-65-6P 446025-66-7P 446025-67-8P
 446025-68-9P 446025-69-0P 446025-70-3P
 446025-71-4P 446025-72-5P 446025-73-6P
 446025-77-0P 446025-78-1P 446025-88-3P


L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 2-A



● HCl

RN 445256-20-2 CAPLUS
 CN Benzamide, N-[[5-(aminomethyl)-2-hydroxyphenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 445256-36-0 CAPLUS
 CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


446025-90-7P 446025-91-8P 446025-93-0P
 446025-95-2P 446025-96-3P 446025-97-4P
 446025-98-5P 446025-99-6P 446026-00-2P
 446026-02-4P 446026-03-5P 446026-04-6P
 446026-05-7P 446026-06-8P 446026-07-9P
 446026-08-0P 446026-09-1P 446026-10-4P
 446026-11-5P 446026-12-6P 446026-13-7P
 446026-14-8P 446026-15-9P 446026-16-0P
 446026-17-1P 446026-18-2P 446026-19-3P
 446026-20-6P 471868-50-5P 471869-06-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of N-[(pyrrolidinocarbonyl)phenyl]amidinophenylacetamides and analogs as antithrombotics)
 RN 445256-14-4 CAPLUS
 CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 445256-38-2 CAPLUS
 CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-2,5-dimethyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




• HCl


RN 445256-41-7 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 445256-42-8 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-2,5-dimethyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 445256-47-3 CAPLUS
CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-30-5 CAPLUS
CN Benzamide, N-[[3-(aminoiminomethyl)phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-31-6 CAPLUS
CN Benamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-37-2 CAPLUS
CN Benamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-3-chloro-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-39-4 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[[3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-41-8 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[[3-bromo-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-43-0 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI)
(CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-44-1 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI)
(CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-45-2 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethenyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI)
(CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-46-3 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI)
(CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-47-4 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-48-5 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-50-9 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-51-0 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-52-1 CAPLUS
CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-53-2 CAPLUS
CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-54-3 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethenyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




● HCl

RN 446025-55-4 CAPLUS
CN Benzenepropanamide, 3-(aminoiminomethyl)-N,N-dimethyl-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
PAGE 1-A



PAGE 2-A




RN 446025-56-5 CAPLUS
CN Benzamide, N-{1-[3-(aminoiminomethyl)phenyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
PAGE 2-A




RN 446025-58-7 CAPLUS
CN Benzeneacetamide, 3-(aminoiminomethyl)-N-ethyl-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446025-57-6 CAPLUS
CN Benzeneacetamide, 3-(aminoiminomethyl)-N,N-dimethyl-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
PAGE 1-A




PAGE 2-A




RN 446025-60-1 CAPLUS
CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-propyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-61-2 CAPLUS
CN Benzamide, N-[1-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-62-3 CAPLUS
CN Benzamide, N-[1-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethyl]-3-bromo-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-63-4 CAPLUS
CN Benzamide, N-[1-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethyl]-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-64-5 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-65-6 CAPLUS
CN Benzenepropanoic acid, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-66-7 CAPLUS
CN Benzenepropanoic acid, 5-(aminoiminomethyl)-2-hydroxy-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-67-8 CAPLUS
CN Benzenepropanoic acid, 3-[(benzoylamino)iminomethyl]-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-68-9 CAPLUS
CN Benzenepropanoic acid, 3-[[[(hexyloxy)carbonyl]amino]iminomethyl]-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-69-0 CAPLUS
CN Benzenepropanoic acid, 3-[(benzoylamino)iminomethyl]-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, propyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-70-3 CAPLUS
CN Benzenepropanoic acid, 3-[imino[[(2,2,2-trichloroethoxy)carbonyl]amino]methyl]-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-71-4 CAPLUS
CN Carbamic acid, [[4-hydroxy-3-[[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]methyl]phenyl]iminomethyl]-, hexyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-72-5 CAPLUS
CN Benzamide, N-[[5-[(benzoylamino)iminomethyl]-2-hydroxyphenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-73-6 CAPLUS
CN Benzamide, N-[[2-hydroxy-5-[(hydroxyamino)iminomethyl]phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl

RN 446025-77-0 CAPLUS
CN Benzamide, N-[[3-(aminoiminomethyl)phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 446025-78-1 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-88-3 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-3-chloro-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-90-7 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-91-8 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-93-0 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-bromo-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-95-2 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-96-3 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-97-4 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethenyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-98-5 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 446025-99-6 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-00-2 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-02-4 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-03-5 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-04-6 CAPLUS
CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanine-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-05-7 CAPLUS
CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)-.beta.-alanine-N-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-06-8 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethenyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-07-9 CAPLUS
CN Benzenepropanamide, 3-(aminoiminomethyl)-N,N-dimethyl-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-08-0 CAPLUS
CN Benzamide, N-[1-[3-(aminoiminomethyl)phenyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-09-1 CAPLUS
CN Benzeneacetamide, 3-(aminoiminomethyl)-N,N-dimethyl-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 446026-12-6 CAPLUS
CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-propyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 2-A



RN 446026-10-4 CAPLUS
CN Benzeneacetamide, 3-(aminoiminomethyl)-N-ethyl-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 446026-11-5 CAPLUS
CN Benzenepropanamide, 3-(aminoiminomethyl)-N-ethyl-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-13-7 CAPLUS
CN Benzamide, N-[1-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-14-8 CAPLUS
CN Benzamide, N-[1-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethyl]-3-bromo-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-15-9 CAPLUS
CN Benzamide, N-[1-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethyl]-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-16-0 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-17-1 CAPLUS
CN Benzamide, N-[1-[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-18-2 CAPLUS
CN Benzenepropanoic acid, 5-(aminoiminomethyl)-2-hydroxy-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-19-3 CAPLUS
CN Benzenepropanoic acid, 3-[[[(hexyloxy)carbonyl]amino]iminomethyl]-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-20-6 CAPLUS
CN Benzamide, N-[[2-hydroxy-5-[(hydroxyamino)iminomethyl]phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 471868-50-5 CAPLUS
CN Carbonic acid, 4-[(benzoylamino)iminomethyl]-2-[[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]methyl]phenyl ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




● HCl

RN 471869-06-4 CAPLUS
CN Benzenepropanamide, 3-(aminomethyl)-N-ethyl-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




IT 471869-69-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of N-[(pyrrolidinocarbonyl)phenyl]amidinophenylacetamides and analogs as antithrombotics)
RN 471869-69-9 CAPLUS
CN Benzamide, N-[[5-cyano-2-(phenylmethoxy)phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



IT 445256-18-8P 445256-19-9P 446026-21-7P
446026-26-2P 446026-27-3P 446026-28-4P

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

446026-30-8P 446026-35-3P 446026-37-5P
446026-39-7P 446026-40-0P 446026-42-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-[(pyrrolidinocarbonyl)phenyl]amidinophenylacetamides and analogs as antithrombotics)
RN 445256-18-8 CAPLUS
CN Benzamide, N-[[5-cyano-2-(phenylmethoxy)phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 445256-19-9 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-(phenylmethoxy)phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




● HCl

RN 446026-21-7 CAPLUS
CN Benzenecetic acid, 3-cyano-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-26-2 CAPLUS
CN Benzamide, 3-chloro-N-[[5-cyano-2-(phenylmethoxy)phenyl]methyl]-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 446026-27-3 CAPLUS
CN Benzenepropanoic acid, 3-cyano-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-28-4 CAPLUS
CN Benzenepropanamide, 3-cyano-N,N-dimethyl-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 446026-30-8 CAPLUS
CN Benzamide, N-[1-[5-cyano-2-(phenylmethoxy)phenyl]ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-35-3 CAPLUS
CN Benzenepropanoic acid, 3-cyano-.beta.-[[4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 446026-37-5 CAPLUS
CN Benzamide, N-[[5-cyano-2-(phenylmethoxy)phenyl]methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-39-7 CAPLUS
CN Benzenepropanoic acid, 5-cyano-2-hydroxy-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 446026-40-0 CAPLUS
CN Benzenepropanoic acid, 5-(aminoiminomethyl)-2-hydroxy-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 446026-42-2 CAPLUS
CN Benzamide, N-[[5-[(hydroxyamino)iminomethyl]-2-(phenylmethoxy)phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A



ACCESSION NUMBER: 2002:615593 CAPLUS
DOCUMENT NUMBER: 137:169323
TITLE: Preparation of benzamidomethylbenzamidines and analogs as factor Xa inhibitors
INVENTOR(S): Ries, Uwe Joerg; Priepe, Henning; Nar, Herbert; Stassen, Jean-Marie; Wienon, Wolfgang
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062778	A2	20020815	WO 2002-EP823	20020126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10104597	A1	20020808	DE 2001-10104597	20010202
PRIORITY APPL. INFO.: DE 2001-10104597 A 20010202 DE 2001-10135435 A 20010726				
OTHER SOURCE(S): MARPAT 137:169323				
GI				




AB Title compds., e.g., R1Z1Z2Z3NH2R [I; R = Z4R4; R1 = cycloalkylamino, cycloalkylaminocarbonyl, 2,5-dihydropyrrolocarbonyl, etc.; R4 = (alkoxycarbonyl)amidino, C(=NH)NHC(=O)CH2CF3, or C(=NH)NHBz and Z4 = 2-hydroxy- or 2-alkoxycarbonyl-1,5-phenylene or R4 = (di)alkylamino, alkoxycarbonylamidino, or C(=NH)NHBz and Z4 = (2-hydroxy)-1,3-phenylene; Z = (un)substituted CH2; Z1 = (un)substituted 1,4-phenylene; Z2 = bond or CH2; Z3 = bond or CO] were prepd. Thus, 4-pyrrolidinocarbonyl-3-methylbenzoic acid was amidated by 3-aminomethyl-4-benzoyloxybenzoxonitrile (prepn. each given) to give, in 3 addnl. steps, title compd. II. Data for biol. activity of I were given.

IT 445256-14-4P 445256-20-2P 445256-32-6P
445256-36-0P 445256-38-2P 445256-41-7P
445256-42-8P 445256-47-3P 446025-30-5P
446025-31-6P 446025-32-7P 446025-33-8P
446025-37-2P 446025-38-3P 446025-39-4P
446025-41-8P 446025-43-0P 446025-44-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzamidomethylbenzamidines and analogs as factor Xa inhibitors)
RN 445256-14-4 CAPLUS
CN Benzamide, N-[[5-[(aminoiminomethyl)-2-hydroxyphenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
PAGE 2-A




● HCl

RN 445256-20-2 CAPLUS
CN Benzamide, N-[[5-(aminomethyl)-2-hydroxyphenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 445256-32-6 CAPLUS
CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
PAGE 1-A




PAGE 2-A




RN 445256-36-0 CAPLUS
CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
PAGE 1-A




PAGE 2-A




● HCl

RN 445256-38-2 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-2,5-dimethyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
PAGE 1-A



PAGE 2-A




● HCl


RN 445256-41-7 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 445256-42-8 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-2,5-dimethyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 445256-47-3 CAPLUS
CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-30-5 CAPLUS
CN Benzamide, N-[[3-(aminoiminomethyl)phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-31-6 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



● HCl


RN 446025-32-7 CAPLUS
CN Benzeneacetamide, 3-(aminomethyl)-N-ethyl-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



● HCl

RN 446025-33-8 CAPLUS
CN Benzenepropanamide, 3-(aminomethyl)-N-ethyl-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 446025-37-2 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-3-chloro-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-38-3 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-39-4 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-41-8 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-bromo-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI)
(CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-43-0 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI)
(CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-44-1 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI)
(CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-45-2 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethenyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI)
(CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-46-3 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-47-4 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-48-5 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-50-9 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-51-0 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-52-1 CAPLUS
CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-53-2 CAPLUS
CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-54-3 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethenyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-55-4 CAPLUS
CN Benzenepropanamide, 3-(aminoiminomethyl)-N,N-dimethyl-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



● HCl

RN 446025-56-5 CAPLUS
CN Benzamide, N-[1-[3-(aminoiminomethyl)phenyl]-2-oxo-2-(1-pyrrolidinylethyl)-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



● HCl


RN 446025-57-6 CAPLUS
CN Benzeneacetamide, 3-(aminoiminomethyl)-N,N-dimethyl-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


PAGE 2-A



● HCl

RN 446025-58-7 CAPLUS
CN Benzeneacetamide, 3-(aminoiminomethyl)-N-ethyl-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-59-8 CAPLUS
CN Benzenepropanamide, 3-(aminoiminomethyl)-N-ethyl-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
NAME)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-60-1 CAPLUS
CN Glycine, 3-[[3-[(aminominoimino)ethyl]phenyl]-N-[(3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl)-beta-alanyl-N-propyl]-ethyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-61-2 CAPLUS
CN Benzamide, N-[1-[5-(aminominoimino)ethyl]-2-hydroxyphenyl]ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-62-3 CAPLUS
CN Benzamide, N-[1-[5-(aminominoimino)ethyl]-2-hydroxyphenyl]ethyl]-3-bromo-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-63-4 CAPLUS
CN Benzamide, N-[1-[5-(aminominoimino)ethyl]-2-hydroxyphenyl]ethyl]-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-64-5 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-65-6 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-66-7 CAPLUS
CN Benzenepropanoic acid, 5-(aminoiminomethyl)-2-hydroxy-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 446025-67-8 CAPLUS
CN Benzenepropanoic acid, 3-[(benzoylamino)iminomethyl]-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-68-9 CAPLUS
CN Benzenepropanoic acid, 3-[[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]iminomethyl]-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 446025-69-0 CAPLUS
CN Benzenepropanoic acid, 3-[(benzoylamino)iminomethyl]-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, propyl ester (9CI) (CA INDEX NAME)


● HCl

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-70-3 CAPLUS
CN Benzenepropanoic acid, 3-[[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]iminomethyl]-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-71-4 CAPLUS
CN Carbamic acid, [[4-hydroxy-3-[[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]methyl]phenyl]iminomethyl]-, hexyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-72-5 CAPLUS
CN Benzamide, N-[[5-[(benzoylamino)iminomethyl]-2-hydroxyphenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-73-6 CAPLUS
CN Benzamide, N-[[2-hydroxy-5-[(hydroxyamino)iminomethyl]phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




• HCl


RN 446025-74-7 CAPLUS
CN Carbonic acid, 4-[(benzoylamino)iminomethyl]-2-[[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]methyl]phenyl ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-77-0 CAPLUS
CN Benzamide, N-[[3-(aminoiminomethyl)phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-78-1 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-79-2 CAPLUS
CN Benzeneacetamide, 3-(aminomethyl)-N-ethyl-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446025-88-3 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-3-chloro-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 2-A




RN 446025-90-7 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 446025-91-8 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-93-0 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-bromo-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-95-2 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-96-3 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-97-4 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethenyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-98-5 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446025-99-6 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-00-2 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-chloro-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-02-4 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethynyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-03-5 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 446026-04-6 CAPLUS
CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 446026-05-7 CAPLUS
CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-06-8 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[3-ethenyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-07-9 CAPLUS
CN Benzenepropanamide, 3-(aminoiminomethyl)-N,N-dimethyl-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-08-0 CAPLUS
CN Benzamide, N-[1-[3-(aminoiminomethyl)phenyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 446026-09-1 CAPLUS
CN Benzeneacetamide, 3-(aminoiminomethyl)-N,N-dimethyl-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 2-A



RN 446026-10-4 CAPLUS
CN Benzeneacetamide, 3-(aminoiminomethyl)-N-ethyl-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 446026-11-5 CAPLUS
CN Benzenepropanamide, 3-(aminoiminomethyl)-N-ethyl-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-12-6 CAPLUS
CN Glycine, 3-[3-(aminoiminomethyl)phenyl]-N-[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]-.beta.-alanyl-N-propyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 446026-13-7 CAPLUS
CN Benzamide, N-[1-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 446026-14-8 CAPLUS
CN Benzamide, N-[1-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethyl]-3-bromo-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-15-9 CAPLUS
CN Benzamide, N-[1-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethyl]-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-16-0 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-.beta.-[[4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-17-1 CAPLUS
CN Benzenepropanoic acid, 3-(aminoiminomethyl)-2-hydroxy-.beta.-[[4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethoxy)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-18-2 CAPLUS
CN Benzenepropanoic acid, 5-(aminoiminomethyl)-2-hydroxy-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-19-3 CAPLUS
CN Benzenepropanoic acid, 3-[[[(hexyloxy)carbonyl]amino]iminomethyl]-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 446026-20-6 CAPLUS
CN Benzamide, N-[[2-hydroxy-5-[(hydroxyamino)iminomethyl]phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




IT 445256-18-8P 445256-19-9P 445256-53-1P
446026-21-7P 446026-26-2P 446026-27-3P
446026-28-4P 446026-30-8P 446026-35-3P
446026-37-5P 446026-39-7P 446026-40-0P
446026-42-2P
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzamidomethylbenzamidines and analogs as factor Xa inhibitors)
RN 445256-18-8 CAPLUS
CN Benzamide, N-[[5-cyano-2-(phenylmethoxy)phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 445256-19-9 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-(phenylmethoxy)phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


PAGE 2-A




● HCl

RN 445256-53-1 CAPLUS
CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monoacetate (9CI) (CA INDEX NAME)
CM 1
CRN 445256-32-6
CMF C24 H28 N4 O4

PAGE 1-A




PAGE 2-A




L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

CM 2
CRN 64-19-7
CMF C2 H4 O2




RN 446026-21-7 CAPLUS
CN Benzenecetic acid, 3-cyano-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 446026-26-2 CAPLUS
CN Benzamide, 3-chloro-N-[[5-cyano-2-(phenylmethoxy)phenyl]methyl]-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-27-3 CAPLUS
CN Benzenepropanoic acid, 3-cyano-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 446026-28-4 CAPLUS
CN Benzenepropanamide, 3-cyano-N,N-dimethyl-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-30-8 CAPLUS
CN Benzamide, N-[[1-[5-cyano-2-(phenylmethoxy)phenyl]ethyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 446026-35-3 CAPLUS
CN Benzenepropanoic acid, 3-cyano-.beta.-[[4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 446026-37-5 CAPLUS
CN Benzamide, N-[[5-cyano-2-(phenylmethoxy)phenyl]methyl]-4-(1-pyrrolidinylcarbonyl)-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 446026-39-7 CAPLUS
CN Benzenepropanoic acid, 5-cyano-2-hydroxy-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4
ANSWER 3 OF 23
CAPLUS
COPYRIGHT 2003 ACS on STN
(Continued)



RN
CN
446026-40-0
CAPLUS
Benzenepropanoic acid, 5-(aminoiminomethyl)-2-hydroxy-.beta.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



HCl

RN
CN
446026-42-2
CAPLUS
Benzamide, N-[[5-[(hydroxyamino)iminomethyl]-2-(phenylmethoxy)phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L4
ANSWER 3 OF 23
CAPLUS
COPYRIGHT 2003 ACS on STN
(Continued)

L4
ANSWER 4 OF 23
CAPLUS
COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:591535 CAPLUS
DOCUMENT NUMBER: 137:154846
TITLE: Preparation of phenylamines or phenylamides as anticoagulants
INVENTOR(S): Ries, Uwe; Priepeke, Henning; Nar, Herbert; Stassen, Jean Marie; Wienen, Wolfgang
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: Ger. Offen., 28 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10104597	A1	20020808	DE 2001-10104597	20010202
US 2002151534	A1	20021017	US 2002-50376	20020116
WO 2002062778	A2	20020815	WO 2002-EP823	20020126
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			DE 2001-10104597 A	20010202
			US 2001-268569P	20010215
			DE 2001-10135435 A	20010726
			DE 2001-10136435 A	20010726
OTHER SOURCE(S):		MARPAT 137:154846		
GI				




I


AB
Title compds. [I; m = 0-2; n = 0, 1; A = bond, (substituted) unbranched C1-3 alkylene; R1 = amino, alkylamino, cycloalkylamino, etc.; R2 = H, F, Cl, Br, Fluorinated alkyl, etc.; R3 = H, alkyl; R4 = H, (substituted) alkyl; R5 = substituted Ph, naphthyl] and salts thereof were prepd. Thus, a mixt. of 3-methyl-4-(pyrrolidin-yl)carbonylbenzylamine (prepn. given), glacial AcOH, and Na[BH3CN] in MeOH was stirred with 3-formyl-4-hydroxybenzonitrile for 2 h at room temp. to give 32% N-(5-cyano-2-hydroxybenzyl)-3-methyl-4-(pyrrolidin-1-ylcarbonyl)benzylamine which was stirred with HCl and (NH4)2CO3 in EtOH for ca. 5 h at room temp. to give 98% N-(5-amidino-2-hydroxybenzyl)-3-methyl-4-(pyrrolidin-1-ylcarbonyl)benzylamine hydrochloride. The latter inhibited factor Xa with IC50 = 0.014 .mu.M.
IT
445256-32-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of phenylamines or phenylamides as anticoagulants)
 RN 445256-32-6 CAPLUS
 CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-[[3-methyl-4-(1-
 pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




IT 445256-14-4P 445256-20-2P 445256-36-0P
 445256-38-2P 445256-41-7P 445256-42-8P
 445256-47-3P 445256-53-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (prepn. of phenylamines or phenylamides as anticoagulants)
 RN 445256-14-4 CAPLUS
 CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-3-methyl-4-(1-
 pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 445256-36-0 CAPLUS
 CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-[[3-methyl-4-(1-
 pyrrolidinylcarbonyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX
 NAME)

PAGE 1-A



L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 PAGE 1-A



PAGE 2-A



● HCl

RN 445256-20-2 CAPLUS
 CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-3-methyl-4-(1-
 pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


PAGE 2-A



● HCl

RN 445256-38-2 CAPLUS
 CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-2,5-dimethyl-4-(1-
 pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 445256-41-7 CAPLUS
 CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-3-methyl-4-(1-
 pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 445256-42-8 CAPLUS
CN Benzamide, N-[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-2,5-dimethyl-4-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 445256-47-3 CAPLUS
CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 445256-53-1 CAPLUS
CN Benzeneacetic acid, 3-(aminoiminomethyl)-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester, monoacetate (9CI) (CA INDEX NAME)
CM 1
CRN 445256-32-6
CMF C24 H28 N4 O4

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




CM 2
CRN 64-19-7
CMF C2 H4 O2




IT 445256-18-8P 445256-19-9P 445256-35-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of phenylamines or phenylamides as anticoagulants)
RN 445256-18-8 CAPLUS
CN Benzamide, N-[[5-cyano-2-(phenylmethoxy)phenyl]methyl]-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 445256-19-9 CAPLUS
 CN Benzamide, N-([5-(aminoiminomethyl)-2-(phenylmethoxy)phenyl]methyl)-3-methyl-4-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN


ACCESSION NUMBER: 2002:31402 CAPLUS
 DOCUMENT NUMBER: 136:102190
 TITLE: Preparation of substituted amines to treat Alzheimer's disease
 INVENTOR(S): Maillaird, Michel; Hom, Court; Gailunas, Andrea; Jagodzinska, Barbara; Fang, Lawrence Y.; John, Varghese; Freskos, John N.; Pulley, Shon R.; Beck, James P.; Tenbrink, Ruth E.
 PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
 SOURCE: PCT Int. Appl., 651 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002512	A2	20020110	WO 2001-US21012	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002128255	A1	20020912	US 2001-896139	20010629
BR 2001012900	A	20030603	BR 2001-12000	20010629
NO 2002006199	A	20030221	NO 2002-6199	20021223
PRIORITY APPLN. INFO.:				
US 2000-215323P P 20000630				
US 2000-252736P P 20001122				
US 2000-255956P P 20001215				
US 2001-268497P P 20010213				
US 2001-279779P P 20010329				
US 2001-295589P P 20010604				
WO 2001-US21012 W 20010629				

OTHER SOURCE(S): MARPAT 136:102190
 GI


L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 2-A





● HCl

RN 445256-35-9 CAPLUS
 CN Benzeneacetic acid, 3-cyano-.alpha.-[[3-methyl-4-(1-pyrrolidinylcarbonyl)benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = H, (un)substituted alkyl, alkenyl, etc.; R4 = XR; X = CO, SO2, a bond, etc.; R = Ph, naphthyl, indanyl, etc.; R5 = (un)substituted alkyl, (CH2)0-3cycloalkyl, etc.], useful in treating Alzheimer's disease and other similar diseases, were prepd. Thus, reacting (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol trifluoroacetate with 5-methyl-N,N-dipropylisophthalamide in the presence of Et3N, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in DMF afforded (1S,2R)-II. The compds. I exhibit an IC50 of < 50 .mu.M against beta-secretase.


IT 388066-79-3P 388066-92-0P 388067-16-1P
 388069-73-6P 388069-77-0P 388069-80-5P
 388069-84-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted amines for treating Alzheimer's disease)
 RN 388066-79-3 CAPLUS
 CN Benzamide, N-([1S,2R]-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-iodophenyl)methyl]amino]propyl)-4-hydroxy-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 388066-92-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-[[[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]amino]carbonyl]-5-methylbenzoyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-16-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-[[[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]amino]carbonyl]-5-methylbenzoyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 388069-73-6 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-4-hydroxy-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-77-0 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-methoxyphenyl)methyl]amino]propyl]-4-hydroxy-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 388069-90-5 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[1-(3-ethylphenyl)-1-methylethyl]amino]-2-hydroxypropyl]-4-hydroxy-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388069-84-9 CAPLUS
CN Benzamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[1-(3-ethylphenyl)cyclopropyl]amino]-2-hydroxypropyl]-4-hydroxy-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

L4 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:833867 CAPLUS
DOCUMENT NUMBER: 135:357774
TITLE: Preparation of phthalic acid diamides as agricultural and horticultural insecticides
INVENTOR(S): Tohnishi, Masanori; Nakao, Hayami; Kohno, Ei-ji; Nishida, Tateki; Furuya, Takashi; Shimizu, Toshiaki; Seo, Akira; Sakata, Kazuyuki; Fujioka, Shinsuke; Kanno, Hideo
PATENT ASSIGNEE(S): Japan
SOURCE: U.S. Pat. Appl. Publ., 114 pp., Cont.-in-part of U.S. Ser. No. 198,391, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001041814	A1	20011115	US 1999-250261	19990216
US 6362369	B2	20020326		
US 2003055287	A1	20030320	US 2002-35132	20020104
US 6559341	B2	20030506		


PRIORITY APPLN. INFO.: JP 1997-339393 A 19971125
JP 1998-51351 A 19980217
US 1998-198391 B2 19981124
US 1999-250261 A3 19990216

OTHER SOURCE(S): MARPAT 135:357774
GI




AB The title compds. [I; R1-R3 = H, CN, cycloalkyl, etc.; X = H, CN, NO2, etc.; n = 1-4; Y = H, halo, CN, etc.; m = 1-5; Z1, Z2 = O, S] which show excellent activities for controlling injurious insects, were prepd. Thus, reaction of 3-nitro-2-ethoxycarbonylbenzoyl chloride with 4-chloro-2-methylaniline in the presence of Et3N in THF followed by treatment of the resulting Et 6-nitro-N-(4-chloro-2-methylphenyl)phthalamate with isopropylamine in dioxane afforded I [R1 = iso-Pr; R2 = R3 = H; X = 3-NO2; Y = 2-Me-4-Cl; Z1 = Z2 = O] which showed excellent insecticidal effect (100% mortality) against diamondback moth and common cutworm. The fluorine-contg. anilines II [R10 = halo, alkyl, alkoxy, CF3; R20, R30, R40 = H or perfluoroalkyl; provided that at least one of R20-R40 is not H atom, and that R30 is neither a pentafluoroethyl nor a n-heptafluoropentyl when R10 = F and each of R20 and R40 = H], useful as a starting material for said phthalic acid diamides were also


L4 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 226971-91-1 CAPLUS
CN Benzamide, 3-iodo-N-[2-methyl-4-(pentafluoroethyl)phenyl]-2-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
prepd.
IT 226968-04-3P 226968-05-4P 226968-06-5P
226971-91-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of phthalic acid diamides as agricultural and horticultural insecticides)
RN 226968-04-3 CAPLUS
CN Benzamide, 2-(1-pyrrolidinylcarbonyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 226968-05-4 CAPLUS
CN Benzamide, N-(5-chloro-2-methylphenyl)-2-nitro-6-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)





RN 226968-06-5 CAPLUS
CN Benzamide, N-[4-(difluoromethoxy)-2-methylphenyl]-2-nitro-6-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:713292 CAPLUS
DOCUMENT NUMBER: 135:272754
TITLE: Preparation of insecticidal anthranilamides
INVENTOR(S): Lahm, George P.; Myers, Brian J.; Selby, Thomas P.; Stevenson, Thomas M.
PATENT ASSIGNEE(S): E.I. Du Pont de Nemours and Company, USA
SOURCE: PCT Int. Appl., 211 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070671	A2	20010927	WO 2001-US9338	20010320
WO 2001070671	A3	20020214		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1265850	A2	20021218	EP 2001-924277	20010320
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001009757	A	20030204	BR 2001-9757	20010320
PRIORITY APPLN. INFO.:			US 2000-191242P	P 20000322
			US 2000-220232P	P 20000724
			US 2000-254635P	P 20001211
			US 2001-262015P	P 20010117
			WO 2001-US9338	W 20010320

OTHER SOURCE(S): MARPAT 135:272754
GI




AB The title compds. [I; A, B = O, S; J = substituted Ph, naphthyl, (un)substituted 5-6 membered heteroarom., arom. 8-10 membered fused heterobicyclic ring; n = 1-4; R1 = H, alkyl, alkenyl, etc.; R2 = H, alkyl, alkoxy, etc.; R3 = H, alkyl, cycloalkyl, etc.; R4 = H, alkyl, halo, etc.], useful for controlling arthropods, were prepd. E.g., a multi-step

L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 synthesis of II which showed excellent level of plant protection (10% or less feeding damage) in test with diamondback moth (DBM), was given.
 IT 362635-67-4P 362635-68-5P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of insecticidal anthranilamides)
 RN 362635-67-4 CAPLUS
 CN Benzamide, 3-methyl-N-(1-methylethyl)-2-[[2-(1-pyrrolidinylcarbonyl)-4-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 362635-68-5 CAPLUS
 CN Benzamide, 3-methyl-N-(1-methylethyl)-2-[[2-(1-pyrrolidinylcarbonyl)-5-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2001:208239 CAPLUS
 DOCUMENT NUMBER: 134:252153
 TITLE: Preparation of benzamides as inhibitors of factor Xa
 INVENTOR(S): Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Eric; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
 PATENT ASSIGNEE(S): Cor Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 224 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019788	A2	20010322	WO 2000-US25196	20000915
WO 2001019788	A3	20010809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1216228	A2	20020626	EP 2000-963452	20000915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014076	A	20021015	BR 2000-14076	20000915
JP 2003509406	T2	20030311	JP 2001-523368	20000915
NO 2002001229	A	20020521	NO 2002-1229	20020312
PRIORITY APPLN. INFO.: US 1999-154332P P 19990917				
US 2000-185746P P 20000229				
WO 2000-US25196 W 20000915				


OTHER SOURCE(S): MARPAT 134:252153
 GI



I


L4 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2001:457084 CAPLUS
 DOCUMENT NUMBER: 138:122298
 TITLE: Recognition-induced control and acceleration of a pyrrole Diels-Alder reaction. [Erratum to document cited in CA135:5288]
 AUTHOR(S): Benkes, R.; Babiloni, M. S.; Hayes, W.; Philp, D.
 CORPORATE SOURCE: School of Chemistry, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
 SOURCE: Tetrahedron Letters (2001), 42(27), 4595
 CODEN: TETLEA; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Figure 1 appeared in place of Figure 2 on page 2378; the correct version of Figure 2 is given.
 IT 341991-10-4P
 RL: SPN (Synthetic preparation); PREP (Preparation) (hydrogen bonding recognition-induced control and acceleration of pyrrole Diels-Alder reaction (Erratum))
 RN 341991-10-4 CAPLUS
 CN 4,7-Imino-2H-isoidole-2-propanoic acid, 1,3,3a,4,7,7a-hexahydro-8-[3-[[methyl(3-methylphenyl)amino]carbonyl]benzoyl]-1,3-dioxo-, methyl ester, (3aR,4R,7S,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

AB The title compds. AQDEGJX [A = alkyl, cycloalkyl, (un)substituted Ph, etc.; Q = a direct link, CH2, CO, etc.; D = a direct link, (un)substituted Ph, naphthyl, etc.; E = a direct link, O, alkyl, etc.; G = alkenylene, cycloalkenylene, phenylene, etc.; J = a direct link, O, S, etc.; X = a (un)substituted Ph, naphthyl, heteroaryl, etc.] having activity against mammalian factor Xa (no data), and useful in vitro or in vivo for preventing or treating coagulation disorders, were prepd. E.g., a 4-step synthesis of the benzamide I was given.
 IT 330942-38-6P 330942-39-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of benzamides as inhibitors of factor Xa)
 RN 330942-38-6 CAPLUS
 CN Benzamide, N-(5-bromo-2-pyridinyl)-2-[[4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 330942-39-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[4-(1-pyrrolidinylcarbonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



L4 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:177305 CAPLUS
 DOCUMENT NUMBER: 135:5288
 TITLE: Recognition-induced control and acceleration of a pyrrole Diels-Alder reaction
 AUTHOR(S): Benne, R.; Babiloni, M. S.; Hayes, W.; Philp, D.
 CORPORATE SOURCE: School of Chemistry, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
 SOURCE: Tetrahedron Letters (2001), 42(12), 2377-2380
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:5288
 AB The formation of two hydrogen bonds between an amidopyridine and a carboxylic acid controls the stereochem. outcome and significantly accelerates the rate of the Diels-Alder cycloaddn. between a benzoylpyrrole and a maleimide.
 IT 341991-10-4P
 RL: SPN (Synthetic preparation); PREP (Preparation) (hydrogen bonding recognition-induced control and acceleration of pyrrole Diels-Alder reaction)
 RN 341991-10-4 CAPLUS
 CN 4,7-Imino-2H-isoindole-2-propanoic acid, 1,3,3a,4,7,7a-hexahydro-8-[3-[[methyl(3-methylphenyl)amino]carbonyl]benzoyl]-1,3-dioxo-, methyl ester, (3aR,4R,7S,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:355614 CAPLUS
 DOCUMENT NUMBER: 131:31808
 TITLE: Preparation of phthalic acid diamides as agricultural and horticultural insecticides
 INVENTOR(S): Tohnishi, Masanori; Nakao, Hayami; Kohno, Eiji; Nishida, Tateki; Furuya, Takashi; Shimizu, Toshiaki; Seo, Akira; Sakata, Kazuyuki; Fujioka, Shinsuke; Kanno, Hideo
 PATENT ASSIGNEE(S): Nihon Nohyaku Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 237 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 919542	A2	19990602	EP 1998-122107	19981123
EP 919542	A3	20000412		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 9893292	A1	19990624	AU 1998-93292	19981120
AU 712421	B2	19991104		
ZA 9810677	A	19990526	ZA 1998-10677	19981123
CZ 291181	B6	20030115	CZ 1998-3799	19981123
EG 22230	A	20021130	EG 1998-1466	19981124
CN 1222506	A	19990714	CN 1998-122688	19981125
CN 1068584	B	20010718		
JP 11240857	A2	19990907	JP 1998-350768	19981125
BR 9805060	A	20000321	BR 1998-5060	19981125
PRIORITY APPLN. INFO.:		JP 1997-339393	A	19971125
OTHER SOURCE(S):		MARPAT 131:31808		




AB The title compds. [I; R1-R3 = H, CN, cycloalkyl, etc.; X = H, CN, NO2, etc.; n = 1-4; Y = H, halo, CN, etc.; m = 1-5; Z1, Z2 = O, S] which show excellent activities for controlling injurious insects, were prepd. Thus, reaction of 3-nitro-2-ethoxycarbonylbenzoyl chloride with 4-chloro-2-methylaniline in the presence of Et3N in THF followed by treatment of the resulting Et 6-nitro-N-(4-chloro-2-methylphenyl)phthalamate with isopropylamine in dioxane afforded I [R1 = iPr; R2 = R3 = H; X = 3-NO2; Y = 2-Me-4-Cl; Z1 = Z2 = O] which showed excellent insecticidal effect (100% mortality) against diamondback moth and common cutworm.
 IT 226968-04-3P 226968-05-4P 226968-06-5P

L4 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


226971-91-1P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of phthalic acid diamides as agricultural and horticultural insecticides)
 RN 226968-04-3 CAPLUS
 CN Benzamide, 2-(1-pyrrolidinylcarbonyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 226968-05-4 CAPLUS
 CN Benzamide, N-(5-chloro-2-methylphenyl)-2-nitro-6-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 226968-06-5 CAPLUS
 CN Benzamide, N-[4-(difluoromethoxy)-2-methylphenyl]-2-nitro-6-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 226971-91-1 CAPLUS

L4 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN Benzamide, 3-iodo-N-[2-methyl-4-(pentafluoroethyl)phenyl]-2-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:779474 CAPLUS
DOCUMENT NUMBER: 130:76175
TITLE: Amide and urea derivatives as ACAT inhibitors and antiarteriosclerotics
INVENTOR(S): Yoshida, Akira; Oda, Kozo; Kasai, Takashi; Shimada, Kamio; Komina, Hiroshi; Hayakawa, Ichio; Ishihara, Sadao; Koga, Teiichiro; Kitazawa, Eiichi; Tokui, Taro
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 127 pp.
CODEN: JXXXXF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10316562	A2	19981202	JP 1998-62571	19980313
PRIORITY APPLN. INFO.:			JP 1997-61379	19970314
OTHER SOURCE(S):	MARPAT 130:76175			
GI				




AB Amide and urea derivs. (I; R1 = alkyl; R2a, R2b, R2c, R2d = H, substituted alkyl, nitro, substituted amino, (protected)OH, alkoxy, cyano, between R2a and R2b with -O-(CH2)m-O- (m = 1-3), alkylthio, alkylsulfinyl, alkylsulfonyl, halogen; R3 = alkyl; R4 = aminocarbonyl, aminocarbonylmethyl) and their pharmacol. acceptable salts are claimed as ACAT inhibitors and antiarteriosclerotics. The ACAT inhibitory action of I was tested, and pharmaceutical hard capsules of I were formulated.
IT 189092-10-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amide and urea derivs. as ACAT inhibitors and antiarteriosclerotics)
RN 189092-10-2 CAPLUS
CN Benzenepropanamide, N-[2-(1,1-dimethylethyl)-5-[(methylamino)carbonyl]phenyl]-2,4-dimethoxy-.beta.-pentyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



L4 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:509180 CAPLUS
DOCUMENT NUMBER: 129:161414
TITLE: Preparation of benzamidine derivatives as anticoagulants
INVENTOR(S): Takayanagi, Masaru; Sagi, Kazuyuki; Nakagawa, Tadakiyo; Yamanashi, Masahiro; Kayahara, Takashi; Takehana, Shunji; et al.
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 453 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9831661	A1	19980723	WO 1998-JP176	19980119
W: AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DX, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9854975	A1	19980807	AU 1998-54975	19980119
AU 731819	B2	20010405		
EP 976722	A1	20000202	EP 1998-900422	19980119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
PRIORITY APPLN. INFO.:			JP 1997-6783	A 19970117
			JP 1997-194602	A 19970718
			JP 1997-331887	A 19971202
			WO 1998-JP176	W 19980119
OTHER SOURCE(S):			MARPAT 129:161414	
GI				




AB The title compds. I [L = CH2CH2, NWCOCH2, etc.; W = H, alkyl, etc.; Y = CH:CH, CONH, etc.; Z = H, alkyl, halo, etc.; when L is CH2CH2, V is benzoyl, cinnamoyl, etc., having substituents; further details on V are given] are prepd. These compds. show anticoagulant effects based on their excellent effects of inhibiting activated blood coagulation factor X, which makes them useful as anticoagulants. In in vitro tests for the inhibition of activated blood coagulation factor X, compds. of this invention showed pIC50 values of 5.5 to 8.1.

L4 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 IT 210961-74-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of benzamidine derivs. as anticoagulants)
 RN 210961-74-3 CAPLUS
 CN Benzamide, N-[(1R)-1-[[3-(aminoiminomethyl)phenoxy]methyl]-2-phenylethyl]-4-(1-pyrrolidinylcarbonyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
 CM 1
 CRN 210961-73-2
 CMF C28 H30 N4 O3

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 alkoxy, etc.; R7 = H or alkyl; n = 0 or 1] were prepd. Thus, 2,4-(MeO)C6H3CHO was condensed with CH2(CO2Et)2 and the BuCH2MgBr-alkylated product converted in 2 steps to 2,4-(MeO)C6H3CH(CH2Bu)CH2CO2H which was amidated by Me 3-amino-4-tert-butylbenzoate (prepn. given) to give, in 2 addnl. steps, title compd. II. Data for biol. activity of I were given.
 IT 189092-10-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of N-(carbamoylphenyl)alkanamides and analogs as cholesterol acyltransferase inhibitors)
 RN 189092-10-2 CAPLUS
 CN Benzenepropanamide, N-[2-(1,1-dimethylethyl)-5-[(methylamino)carbonyl]phenyl]-2,4-dimethoxy-.beta.-pentyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1997:317732 CAPLUS
 DOCUMENT NUMBER: 126:293189
 TITLE: Preparation of N-(carbamoylphenyl)alkanamides and analogs as cholesterol acyltransferase inhibitors
 Yoshida, Akira; Oda, Kozo; Kasai, Takashi; Shimada, Kousei; Kogen, Hiroshi; Hayskawa, Ichiro; Ishihara, Sadao; Koga, Teiichiro; Kitazawa, Eiichi; Tokui, Taro
 Sankyo Co., Ltd., Japan
 Eur. Pat. Appl., 280 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 763524	A1	19970319	EP 1996-306781	19960918
EP 763524	B1	20000823		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2185737	AA	19970319	CA 1996-2185737	19960917
NO 9603896	A	19970319	NO 1996-3896	19960917
AU 9665659	A1	19970320	AU 1996-65659	19960917
AU 712467	B2	19991104		
ZA 9607840	A	19970407	ZA 1996-7840	19960917
RU 2128165	C1	19990327	RU 1996-118358	19960917
JP 09143137	A2	19970603	JP 1996-246481	19960918
CN 1171394	A	19980128	CN 1996-119249	19960918
US 5880147	A	19990309	US 1996-715589	19960918
AT 195724	E	20000915	AT 1996-306781	19960918
ES 2151640	T3	20010101	ES 1996-306781	19960918
US 6040339	A	20000321	US 1998-86402	19980528
HK 1011349	A1	20010119	HK 1998-112513	19981130
PRIORITY APPLN. INFO.:			JP 1995-238042	A 19950918
			US 1996-715589	A3 19960918


OTHER SOURCE(S): MARPAT 126:293189
 GI




AB RCHR1CH2(NH)nCONHR3 [I; R = (un)substituted Ph; R1,R3 = alkyl; Z = 1,2-phenylene further substituted by A1CONR5aR5b, A1CN, A2NR7CONR5aR5b, etc.; A1 = bond or alk(en)ylene; A2 = alk(en)ylene; R5a,R5b = H, alkyl,

L4 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1996:202914 CAPLUS
 DOCUMENT NUMBER: 124:277963
 TITLE: Non-Peptide Cholecystokinin-B/Gastrin Receptor Antagonists Based on Bicyclic, Heteroaromatic Skeletons
 AUTHOR(S): Kalindjian, S. Barret; Buck, Ildiko M.; Davies, Jonathan M. R.; Dunstone, David J.; Hudson, Martin L.; Low, Caroline M. R.; McDonald, Iain M.; Pether, Michael J.; Steel, Katherine I. M.; et al.
 CORPORATE SOURCE: James Black Foundation, London, SE24 9JE, UK
 SOURCE: Journal of Medicinal Chemistry (1996), 39(9), 1806-15
 CODEN: JMCMA; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A series of potent and selective cholecystokinin-B/gastrin receptor antagonists based on the dibenzobicyclo[2.2.2]octane (BCO) skeleton which have recently been described were found to show species-dependent behavior when examd. in rat and dog models. We now report the discovery of compds. in which the BCO skeleton has been replaced with bicyclic, heteroarom. frameworks, such as a 5,6-disubstituted indole or benzimidazole. These new ligands maintain the affinity the affinity and selectivity profile of the previous compds. in vitro but show a much more consistent behavior pattern in vivo. Representative examples of this class of compd. have been shown to inhibit pentagastrin-stimulated acid secretion when administered i.v. at doses of 0.1 .mu.mol kg-1 or less.
 IT 167990-56-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroarom. skeletons)
 RN 167990-56-9 CAPLUS
 CN D-Proline, 1-[[[3-[[[tricyclo[3.3.1.1.3,7]dec-1-ylmethyl]amino]carbonyl]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1996:25340 CAPLUS
DOCUMENT NUMBER: 124:56894
TITLE: Polyimide Formation through the Palladium-Mediated Carbonylation and Coupling of Bis(o-iodo amides) and Diamines
AUTHOR(S): Perry, Robert J.; Tunney, Scott E.; Wilson, B. David
CORPORATE SOURCE: Eastman Kodak Company, Rochester, NY, 14650-1705, USA
SOURCE: Macromolecules (1996), 29(3), 1014-20
CODEN: MAMOBX; ISSN: 0024-9297
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Reactions between bis(o-iodo amides) and diamines in the presence of a palladium catalyst and a base at elevated (90 psig) carbon monoxide (CO) pressures give intermediate poly(amic amide) polymers which can be thermally ring-closed to the fully imidized polyimides. Model studies indicate that competing side reactions are suppressed and the intermediate o-diamide is stabilized when diisopropylamides are used.
IT 171261-72-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
{model reaction product; polyimide formation through the Pd-mediated carbonylation and coupling of bis(o-iodo amides) and diamines}
RN 171261-72-6 CAPLUS
CN Benzamide, N-phenyl-2-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:1005479 CAPLUS
DOCUMENT NUMBER: 124:176900
TITLE: Protein Structure-Based Design of Combinatorial Libraries: Discovery of Non-Peptide Binding Elements to Src SH3 Domain
AUTHOR(S): Combs, Andrew P.; Kapoor, Tarun M.; Feng, Sibor; Chen, James K.; Daude-Snow, Lygia F.; Schreiber, Stuart L.
CORPORATE SOURCE: Howard Hughes Medical Institute, Harvard University, Cambridge, MA, 02138, USA
SOURCE: Journal of the American Chemical Society (1996), 118(1), 287-8
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB An approach to the discovery of cell permeable ligands to protein receptors is reported. By examg. the 3-dimensional structures of SH3-peptide complexes detd. by multidimensional NMR, a solid phase, encoded combinatorial synthesis was rationally designed to deliver nonpeptide binding elements to the site of a key specificity-detg. pocket in SH3 domains. Fifteen ligands to the SH3 domain from the protein tyrosine kinase Src were selected from a pool of >1,000,000 spatially sepd. mols. These were resynthesized and individually analyzed for their ability to bind to the Src SH3 domain. They were shown to be among the highest affinity SH3 ligands known, and they are the first SH3 ligands to use nonpeptide binding elements. The strategy used in this study is expected to be applicable to the discovery of ligands to proteins in general in general.
IT 173911-61-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(protein structure-based design of combinatorial libraries discovery of nonpeptide binding elements to Src SH3 domain)
RN 173911-61-0 CAPLUS
CN L-Prolinamide, 1-[3-[[[4-(aminomethyl)phenyl]methyl][4-[[[3-nitro-5-[[3-[[3-(trifluoromethyl)benzoyl]amino]-1-pyrrolidinyl]carbonyl]benzoyl](4-piperidinylmethyl)amino]methyl]cyclohexyl]carbonyl]amino]-1-oxopropyl]-L-prolyl-L-leucyl-L-prolyl-L-prolyl-L-leucyl-, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:801429 CAPLUS
DOCUMENT NUMBER: 123:256711
TITLE: Preparation of gastrin and CCK receptor ligands
INVENTOR(S): Kalindjian, Sarkis Barret; Steel, Katherine Isobel Mary; Pether, Michael John; Davies, Jonathan Michael Richard; Low, Caroline Minli Rachel; Hudson, Martin Lyn; Buck, Ildiko Maria; McDonald, Iain Mair; Dunstone, David John; Tozer, Matthew John
PATENT ASSIGNEE(S): James Black Foundation Ltd., UK
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXDZ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9504720	A2	19950216	WO 1994-GB1741	19940809
WO 9504720	A3	19950803		
W:	AM, AT, AU, BE, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN			
RW:	KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9473478	A1	19950228	AU 1994-73478	19940809
AU 682051	B2	19970918		
EP 720601	A1	19960710	EP 1994-922318	19940809
EP 720601	B1	20001025		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
JP 09502430	T2	19970311	JP 1994-506306	19940809
HU 75301	A2	19970528	HU 1996-70	19940809
AT 197146	E	20001115	AT 1994-922318	19940809
ES 2152989	T3	20010216	ES 1994-922318	19940809
PL 181782	B1	20010928	PL 1994-312960	19940809
ZA 9405998	A	19960212	ZA 1994-5998	19940810
GB 2290539	A1	19960103	GB 1995-2503	19950209
WO 9532949	A1	19951207	WO 1995-GB1194	19950525
W:	AM, AT, AU, BE, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT			
RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9525342	A1	19951221	AU 1995-25342	19950525
EP 763026	A1	19970319	EP 1995-919561	19950525
EP 763026	B1	20030326		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
JP 10504525	T2	19980506	JP 1995-500483	19950525
AT 235470	E	20030415	AT 1995-919561	19950525
ZA 9504315	A	19961126	ZA 1995-4315	19950526
NO 9600488	A	19960315	NO 1996-488	19960206
FI 9600572	A	19960207	FI 1996-572	19960207
US 5795907	A	19980818	US 1996-583008	19960318
US 5912260	A	19990615	US 1996-737725	19961219
US 5919829	A	19990706	US 1998-64849	19980423
PRIORITY APPLN. INFO.:			GB 1993-16608	A 19930810
			GB 1994-10688	A 19940527
			WO 1994-GB1741	W 19940809

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 GE 1995-2503 A 19950209
 WO 1995-GB1194 W 19950525
 OTHER SOURCE(S): MARPAT 123:256711
 GI



II


AB Title compds. [e.g. I; A = atoms to complete a bicyclic ring system; R1 = halo, NH2, cyano, OH, alkyl, CO2H, etc.; 1 of X, W = CO and the other = CO, SO, SO2; Y = NR3R4, hydrocarbyloxy, etc.; R3 = H, hydrocarbyl, etc.; R4 = H, alkyl, (un) esterified CH2CO2H; Z = OH, alkoxy, OPh, (un)substituted NH2, NHZ1R, etc.; R = H, cyano, alkyl, CH2OH, CO2H, etc.; Z1 = alkylene; m = 0-6] were prep'd. Thus, 4-methylphthalic anhydride was converted in 6 steps to indole-5,6-dicarboxylic anhydride which was amidated by adamantane-1-methylamine and the product amidated by (S)-3,5-(PhH2CO2C)2C6H3NHCOCH(NH2)CH2Ph (prepn. given) to give, in 2 addnl. steps, title compd. (S)-II the di-N-methyl-D-glucamine salt of which had pK_i of 9.4 for binding at mouse cortex CCKB receptors in vitro.

IT 167990-56-9P 167990-57-0P 167990-58-1P
 167990-59-2P 167990-62-7P 167990-63-8P
 167990-65-0P 167990-66-1P 167990-67-2P
 167990-68-3P 167990-69-4P 167990-70-7P
 167990-71-8P 167990-72-9P 167990-75-2P
 167990-76-3P 167990-80-9P 167990-81-0P
 167991-75-5P 167991-76-6P 167991-77-7P
 167991-78-8P 167991-93-7P 167991-94-8P
 167993-49-9P 167993-50-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of gastrin and CCK receptor ligands)
 RN 167990-56-9 CAPLUS
 CN D-Proline, 1-[[3-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN L-Proline, 1-[[3-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167990-59-2 CAPLUS
 CN L-Proline, 1-[[3-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 167990-58-1
 CMF C28 H32 N2 O4


Absolute stereochemistry.



CM 2


CRN 6284-40-8
 CMF C7 H17 N O5

Absolute stereochemistry.



RN 167990-62-7 CAPLUS

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 167990-57-0 CAPLUS
 CN D-Proline, 1-[[3-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 167990-56-9
 CMF C28 H32 N2 O4


Absolute stereochemistry.



CM 2

CRN 6284-40-8
 CMF C7 H17 N O5


Absolute stereochemistry.



RN 167990-58-1 CAPLUS


L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN L-Proline, 1-[[3-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167990-63-8 CAPLUS
 CN D-Proline, 1-[[3-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167990-65-0 CAPLUS
 CN D-Proline, 1-[[3-[[[methyl(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167990-66-1 CAPLUS

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN D-Proline, 1-[[3-[[methyl(tricyclo[3.3.1.1³,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 167990-65-0
 CMF C29 H34 N2 O4


Absolute stereochemistry.



CM 2

CRN 6284-40-8
 CMF C7 H17 N O5


Absolute stereochemistry.



RN 167990-67-2 CAPLUS
 CN D-Alanine, N-[1-[[3-[[tricyclo[3.3.1.1³,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-D-prolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 167990-68-3 CAPLUS
 CN Glycine, N-[1-[[3-[[tricyclo[3.3.1.1³,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-D-prolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167990-69-4 CAPLUS
 CN L-Alanine, N-[1-[[3-[[methyl(tricyclo[3.3.1.1³,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-D-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 167990-70-7 CAPLUS
 CN L-Alanine, N-[1-[[3-[[methyl(tricyclo[3.3.1.1³,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-D-prolyl]-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 167990-69-4
 CMF C32 H39 N3 O5


Absolute stereochemistry.



CM 2

CRN 6284-40-8
 CMF C7 H17 N O5

Absolute stereochemistry.




RN 167990-71-8 CAPLUS

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

CN Glycine, N-[1-[[3-[[methyl(tricyclo[3.3.1.1³,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-D-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167990-72-9 CAPLUS
 CN Glycine, N-[1-[[3-[[methyl(tricyclo[3.3.1.1³,7]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-D-prolyl]-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 167990-71-8
 CMF C31 H37 N3 O5

Absolute stereochemistry.




CM 2

CRN 6284-40-8
 CMF C7 H17 N O5


Absolute stereochemistry.

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 167990-75-2 CAPLUS
CN D-Alanine, N-[1-[[3-[[{tricyclo[3.3.1.1³,7]dec-1-ylmethyl}amino]carbonyl]-2-naphthalenyl]carbonyl]-2-pyrrolidinyl]acetyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167990-76-3 CAPLUS
CN D-Alanine, N-[1-[[3-[[{tricyclo[3.3.1.1³,7]dec-1-ylmethyl}amino]carbonyl]-2-naphthalenyl]carbonyl]-L-prolyl-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 167990-75-2
CMF C32 H39 N3 O5

Absolute stereochemistry.




L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



CM 2


CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



RN 167991-75-5 CAPLUS
CN Glycine, N-[1-[[6-[[{tricyclo[3.3.1.1³,7]dec-1-ylmethyl}amino]carbonyl]-1H-benzimidazol-5-yl]carbonyl]-D-prolyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167991-76-6 CAPLUS
CN Glycine, N-[1-[[6-[[{tricyclo[3.3.1.1³,7]dec-1-ylmethyl}amino]carbonyl]-1H-benzimidazol-5-yl]carbonyl]-D-prolyl-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)


CM 1

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

CM 2


CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



RN 167990-80-9 CAPLUS
CN D-Proline, 1-[4,5-dichloro-2-[2-oxo-2-[[{tricyclo[3.3.1.1³,7]dec-1-ylmethyl}amino]ethyl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167990-81-0 CAPLUS
CN D-Proline, 1-[4,5-dichloro-2-[2-oxo-2-[[{tricyclo[3.3.1.1³,7]dec-1-ylmethyl}amino]ethyl]benzoyl]-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 167990-80-9
CMF C25 H30 Cl2 N2 O4

Absolute stereochemistry.

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

CRN 167991-75-5
CMF C27 H33 N5 O5


Absolute stereochemistry.



CM 2


CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



RN 167991-77-7 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[[[1-[[6-[[{tricyclo[3.3.1.1³,7]dec-1-ylmethyl}amino]carbonyl]-1H-benzimidazol-5-yl]carbonyl]-2-pyrrolidinyl]carbonyl]amino-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167991-78-8 CAPLUS
CN D-Glucitol, 1-deoxy-1-(methylamino)-, (S)-5-[[[1-[[6-

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 [[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-1H-benzimidazol-5-yl]carbonyl]-2-pyrrolidinyl]carbonyl]amino]-1,3-benzenedicarboxylate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 167991-77-7
 CMF C33 H35 N5 O7


Absolute stereochemistry.



CM 2

CRN 6284-40-8
 CMF C7 H17 N O5


Absolute stereochemistry.



RN 167991-93-7 CAPLUS
 CN D-Alanine, N-[1-[[6-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-1H-indol-5-yl]carbonyl]-D-prolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 167993-49-9 CAPLUS
 CN L-Alanine, N-[1-[[5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-1H-indol-6-yl]carbonyl]-D-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167993-50-2 CAPLUS
 CN L-Alanine, N-[1-[[5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-1H-indol-6-yl]carbonyl]-D-prolyl]-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 167993-49-9
 CMF C29 H36 N4 O5

Absolute stereochemistry.



CM 2

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 167991-94-8 CAPLUS
 CN D-Alanine, N-[1-[[6-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-1H-indol-5-yl]carbonyl]-D-prolyl]-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 167991-93-7
 CMF C29 H36 N4 O5

Absolute stereochemistry.



CM 2


CRN 6284-40-8
 CMF C7 H17 N O5

Absolute stereochemistry.

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


CRN 6284-40-8
 CMF C7 H17 N O5

Absolute stereochemistry.




IT 167992-78-1P 167992-79-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of gastrin and CCK receptor ligands)
 RN 167992-78-1 CAPLUS
 CN D-Proline, 1-[[3-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167992-79-2 CAPLUS
 CN D-Alanine, N-[1-[[3-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-D-prolyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

L4 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1994:164907 CAPLUS
DOCUMENT NUMBER: 120:164907
TITLE: Preparation of proline containing peptide analogs as specific inhibitors of prolyl endopeptidase
INVENTOR(S): Kobayashi, Koji; Nishii, Kazuhiko; Iwata, Kunio; Uchida, Itsuro
PATENT ASSIGNEE(S): Nippon Tobacco Sangyo, Japan; Yoshitomi Pharmaceutical
SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05201970	A2	19930810	JP 1992-50136	19920124
PRIORITY APPLN. INFO.:			JP 1992-50136	19920124
OTHER SOURCE(S):			MARPAT 120:164907	

GI




AB Title compds. [I; A = O, NH, CONH, single bond; B = Q-Q2, (CH2)k, NHCHR1; k = 1-3; R1 = H, lower alkyl; W = 2-oxo-1-pyrrolidinyl, R2C6H4; R2 = H, halo, lower alkyl; X = S, SO, SO2, O, NH; R = Q3, lower alkyl; l = 0-3; Y, Z = H, halo, lower (fluoro)alkyl, NH2, NO2, OH, lower alkoxy; or YZ may form (un)satd. 5- or 6-membered ring; n = 1-6] are prepd. I specifically inhibit decompn. and inactivation of proline-contg. brain hormones and neurotransmitters (TSH-releasing hormone, substance P, neurotensin, and vasopressin) and thus are useful for the improvement of said hormone- and neurotransmitters-related diseases and for the prevention and treatment of dementia and amnesia including Alzheimer's disease, directly acting on the core symptoms of dementia. Thus, NaH was stirred with DMSO at 70.degree. and mixt. was dild. with THF, cooled to -5.degree., and then treated with a soln. of Me3Si in DMSO followed by a soln. of N-tert-butoxycarbonyl-L-prolinol in THF to give, after reacting at 0.degree. for 1 h, (2S)-1-(tert-butoxycarbonyl)-2-(1,2-epoxyethyl)pyrrolidine. The latter compd. was refluxed with 4-chlorophenol in MeOH contg. NaOMe to give

L4 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
(2S)-1-(tert-butoxycarbonyl)-2-[2-(4-chlorophenoxy)-1-hydroxyethyl]pyrrolidine. The latter compd. was deprotected with 4N HCl in 1,4-dioxane and then condensed with benzyl N-(3-phenylpropionyl)-L-prolinate (prepn. given) using 1-ethyl-2-(3-diethylaminopropyl)carbodiimide, hydroxybenzotriazole, and N-methylmorpholine in DMF to give (2S)-2-[2-(4-chlorophenoxy)-1-hydroxyethyl]-1-[N-(3-phenylpropionyl)-L-prolyl]pyrrolidine which was oxidized with SO3-pyridine complex in DMSO to give (2S)-2-(4-chlorophenoxyacetyl)-1-[N-(3-phenylpropionyl)-L-prolyl]pyrrolidine (II). II at 1 .mu.M and (2S)-1-[N-(4-fluorobenzylaminocarbonyl)-L-prolyl]-2-(4-fluorophenoxyacetyl)pyrrolidine at 0.1 .mu.M inhibited 99% prolyl endopeptidase and did not inhibit trypsin, chymotrypsin, leucine aminopeptidase, elastase, and cathepsin.
IT 153451-27-5P
RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as intermediate for prolyl endopeptidase inhibitor)
RN 153451-27-5 CAPLUS
CN Benzamide, 2-[[2-(1-hydroxy-2-phenoxyethyl)-1-pyrrolidinyl]carbonyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT 153451-03-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. of, as prolyl endopeptidase inhibitor)
RN 153451-03-7 CAPLUS
CN Benzamide, 2-[[2-(phenoxyacetyl)-1-pyrrolidinyl]carbonyl]-N-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1992:633813 CAPLUS
DOCUMENT NUMBER: 117:233813
TITLE: Exploratory studies of .alpha.-silylamino- and .alpha.-silylamido-2,5-cyclohexadien-1-one SET photochemistry. Methodology for synthesis of functionalized hydroisoquinolines
AUTHOR(S): Jung, Young Shik; Swartz, William H.; Xu, Wei; Mariano, Patrick S.; Green, Neal J.; Schultz, Arthur G.
CORPORATE SOURCE: Dep. Chem. Biochem., Univ. Maryland, College Park, MD, 20742, USA
SOURCE: Journal of Organic Chemistry (1992), 57(22), 6037-47
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 117:233813
GI




AB The electron-transfer (SET) photochem. of selected .alpha.-silylamino and .alpha.-silylamido 2,5-cyclohexadienones, e.g., I, has been explored with the intent of developing a novel and potentially efficient method for functionalized hydroisoquinoline synthesis. These substances, prepd. by Birch redn.-alkylation-oxidn. sequences, were found to undergo 9,10-dicyanoanthracene-SET-sensitized radical cyclization to form hydroisoquinolines, e.g., II, in a highly regio- and stereoselective fashion and in modest to good yields. In contrast, the major direct irrads. reaction pathway followed by the .alpha.-silylamido-substituted systems involves type A rearrangement to bicyclic cyclohexenones or phenols. Direct irrads. of the .alpha.-silylamino analogs, on the other hand, brings about near-exclusive conversion to the corresponding hydroisoquinolines. The synthetic and mechanistic features of this study are described.

IT 143925-63-7P 143925-64-8P
RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
RN 143925-63-7 CAPLUS
CN Benzeneacetamide, 5-hydroxy-N-(phenylmethyl)-2-(1-pyrrolidinylcarbonyl)-N-[(trimethylsilyl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 143925-64-8 CAPLUS
 CN Benzeneacetamide, 3-hydroxy-N-(phenylmethyl)-2-(1-pyrrolidinylcarbonyl)-N-[(trimethylsilyl)methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1992:194147 CAPLUS
 DOCUMENT NUMBER: 116:194147
 TITLE: Preparation of 1-acylpyrrolidine-2-carboxaldehydes and analogs as psychoanaleptic agents
 INVENTOR(S): Faraci, W. Stephen; Nagel, Arthur A.; Spencer, Robin W.; Vinick, Fredic J.
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: PCT Int. Appl., 60 pp.
 CODEN: FIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9118891	A1	19911212	WO 1991-US3390	19910515
W: CA, FI, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
EP 536163	A1	19930414	EP 1991-910005	19910515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05506442	T2	19930922	JP 1991-509445	19910515
JP 2511605	B2	19960703		
US 5847155	A	19981208	US 1996-592221	19960126
			US 1990-532534	19900604
			WO 1991-US3390	19910515
			US 1993-960374	19930127

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 116:194147
 GI




AB Title compds. [I; X = S, (CH₂)_n; Y = H, CHO, COCF₃, hydroxyalkyl, etc.; Z = 1-fluorenyl, 2-(1-naphthoyl)phenyl, 2-arylphenyl, 2-carbamoylcyclopent(en)yl, etc.; n = 1, 2] were prepd. as prolyl endopeptidase inhibitors (no data). Thus, indole-2-carboxylic acid was condensed with ClCO₂CH₂Ph and the product condensed with (S)-(+)-pyrrolidinemethanol to give after oxidn., title compd. II.
 IT 140486-11-9P 140486-12-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as psychoanaleptic agent)
 RN 140486-11-9 CAPLUS
 CN Benzamide, 2-[[2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-N-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
Absolute stereochemistry.

RN 140486-12-0 CAPLUS
 CN Benzamide, 2-[(2-formyl-1-pyrrolidinyl)carbonyl]-N-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1991:514208 CAPLUS
 DOCUMENT NUMBER: 115:114208
 TITLE: Scope of phthalimido chemistry. I. Extension of utility by conversion to the OPCB protecting group
 AUTHOR(S): Astleford, Bret; Weigel, Leland O.
 CORPORATE SOURCE: Chem. Process Res. Dev. Div., Lilly Res. Lab., Indianapolis, IN, 46285, USA
 SOURCE: Tetrahedron Letters (1991), 32(28), 3301-4
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI





AB The susceptibility of the phthalimido protecting group to basic and nucleophilic conditions has been overcome by conversion to o-pyrrolidinocarbonylbenzamides (OPCBs). Thus, reaction of phthalimides, e.g. I, with pyrrolidine in THF gave 83-98% OPCBs, e.g. II. The OPCBs are stable to non-equilibrating basic and mild acidic conditions. The OPCB group can be either cleaved to give the amine or converted back to the imide.
 IT 135382-78-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. and intramol. cyclocondensation of, phthalimide from)
 RN 135382-78-4 CAPLUS
 CN Benzamide, N-(phenylmethyl)-2-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1984:191959 CAPLUS
 DOCUMENT NUMBER: 100:191959
 TITLE: Organophosphorus compounds. XIX. Synthesis of 2,3-dihydro-1H-1,2-benzazaphosphole 2-oxides, variously substituted on nitrogen and phosphorus, by nitrogen-phosphorus cyclization of zwitterionic intermediates
 AUTHOR(S): Collins, David J.; Drygala, Peter F.; Swan, John M.
 CORPORATE SOURCE: Dep. Chem., Monash Univ., Clayton, 3168, Australia
 SOURCE: Australian Journal of Chemistry (1983), 36(12), 2517-36
 CODEN: AJCHAS; ISSN: 0004-9425
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 100:191959
 GI

L4 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



AB 2-Phenyl-2,3-dihydro-1H-1,2-benzazaphosphole 2-oxide (I; R = H) was prepd. by thermolysis of the corresponding zwitterionic aminophosphinic acid (II) or II.HCl. Thermolysis of Me or Et (2-aminobenzyl)phenylphosphinate was accompanied by intermol. O .fwdarw. N transalkylation to give, after cyclization, I (R = Me, Et, resp.). Reaction of 2-phthalimidobenzyl bromide with MeP(OEt)2 gave Et (2-phthalimidobenzyl)methylphosphinate (III). Hydrolysis of III afforded (2-aminobenzyl)methylphosphinic acid, and thermolysis of this produced 2-methyl-2,3-dihydro-1H-1,2-benzazaphosphole 2-oxide (IV). 1-Methyl-2-methoxy-2,3-dihydro-1H-1,2-benzazaphosphole 2-oxide was synthesized analogously. Base-catalyzed N-alkylation of the benzazaphosphole derivs. I (R = H) and IV was readily achieved, and the interconversion of 2-oxides and 2-sulfides was accomplished by conventional methods.

IT 90043-17-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 90043-17-7 CAPLUS
 CN Phosphinic acid, phenyl{[2-[[2-(1-pyrrolidinylcarbonyl)benzoyl]amino]phenylmethyl]- (SCI) (CA INDEX NAME)

Page 68 08/18/2003

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

105.58

255.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION



CA SUBSCRIBER PRICE

-14.97

-14.97

STN INTERNATIONAL LOGOFF AT 12:40:41 ON 18 AUG 2003

C:\STNEXP4\QUERIES\10050376.str



chain nodes :

7 13 14 15 16 17 18 19

ring nodes :

1 2 3 4 5 6 8 9 10 11 12

chain bonds :

6-14 7-8 7-13 14-15 15-16 15-19 16-17 17-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12

exact/norm bonds :

7-8 7-13 8-9 8-12 9-10 10-11 11-12 15-16 15-19 16-17

exact bonds :

6-14 14-15 17-18

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS
17:CLASS 18:Atom 19:CLASS 24:CLASS